Dr. Kevin Jacob Yeroushalmi, MD

Dr. Yeroushalmi practices at Northpointe Physicians Group in Brooksville, Florida.

Dr. Yeroushalmi's NPI, 1831552165, was assigned on April 4, 2016. Dr. Yeroushalmi graduated from Tel Aviv University Sackler in 2016. Dr. Yeroushalmi holds New York license 299499.

Dr. Yeroushalmi's primary practice is Northpointe Physicians Group, at 11373 Cortez Blvd, Brooksville, FL 34613 in Hernando County. The practice phone is (352) 797-3500.

Dr. Yeroushalmi's primary practice is Northpointe Physicians Group in Brooksville, Florida. Dr. Yeroushalmi is also affiliated with Peconic Bay Medical Center. The medical group on file is Nassau University Medical Center (NUMC), Department of Psychiatry and Behavioral Sciences. Dmand AI also links Dr. Yeroushalmi to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Yeroushalmi practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Yeroushalmi's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Yeroushalmi's licenses on file in 2 states: New York and Florida.

CMS data shows 243 Medicare services from Dr. Yeroushalmi across 8 procedure codes in 2024, for 168 Medicare patients. Medicare paid $28,356 for them.

CMS counts 168 Medicare patients who saw Dr. Yeroushalmi in 2024. The largest group is 65 to 74, with 66 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Yeroushalmi's median patient age at 63, with 46% women.

In 2024, Dr. Yeroushalmi wrote 103 Medicare Part D claims for 72 patients. 88% of them were for generic drugs. CMS names the drug for 58 of them, across 3 drugs with 11 or more claims each, at $261 in total drug cost. In 2022, CMS named 52 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Yeroushalmi for performance year 2024, reported through an alternative payment model (APM). Dr. Yeroushalmi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Yeroushalmi as offering telehealth. CMS counts 150 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Yeroushalmi, more than 85% of the clinicians it reports for that procedure.

Dmand AI links 6 papers to Dr. Yeroushalmi, published from 2012 to 2022. 2012 was the busiest year, with 2. Dr. Yeroushalmi's most frequent co-authors are Jiten Desai, Shiva Mukund Arjun, MD and Shunichi Homma, MD.

CMS Open Payments shows 79 general payments to Dr. Yeroushalmi from 8 drug and device companies from 2023 to 2025. Travel and lodging make up the largest share, 60% of the total. Boston Scientific Corporation paid the most, $5,338.

Dr. Yeroushalmi graduated from Tel Aviv University Sackler in 2016.